OBJECTIVES Health economic analysis (HEA) has been required since 2008 as a part of drug reimbursement applications submitted to the State Institute for Drug Control (SUKL). In 2013, SUKL introduced a formal health economic guideline, mostly based on the Czech Pharmacoenomic Society´s guideline published in 2011. The aim of this study was to assess the impact of guideline implementation on the quality of submitted HEAs.  METHODS We reviewed all (18) applications for new innovative drugs with prescription limited to specialized centers, in which the final decision was issued and came into force between 1/2013-6/2014. The HEAs were described in terms of type of analysis and further confronted with a ‘HEA checklist‘ to identify common deficiencies in submitted HEAs. All check-lists were peer-reviewed to ensure objectivity. Our results were compared with previously published research (assessing HEAs submitted in 2008-2009 before the guideline release). RESULTS All investigated dossiers contained HEA. Nine of them (50%) were cost-effectiveness analysis (outcome expressed mostly in LYGs) and nine (50%) were cost-utility analyses (outcome in QALYs). In general, the quality of HEAs was higher compared to the previous research, with ‘evidence completeness’ and ‘uncertainty’ being the most commonly marked as ‘unsatisfactory’ in the HEA checklist (less than 50%). Our results showed that 1/3 HEAs fell into the ‘best’ category (80-100% ‘satisfactory’ questions), while none of HEAs fell into this category in previous research. CONCLUSIONS The present analysis showed a trend in higher quality of submitted analyses (1/2013-6/2014) compared with years 2008-2009.